2 Healthcare Stocks to Buy in a Bear Market

Johnson & Johnson and Abbott Laboratories are presented as defensive, diversified healthcare stocks well suited for a bear market, each with long dividend-raise streaks (Johnson & Johnson: 63 years; Abbott: 54 years). J&J's broad pharmaceutical and medtech franchises and top-tier credit rating underpin steady revenue and profit generation, while Abbott's device, diagnostics and nutrition mix — led by FreeStyle Libre continuous glucose monitoring and a recent cancer-diagnostics acquisition — support continued growth and income-oriented appeal.

Analysis

Market structure: Durable, diversified healthcare winners are JNJ and ABT — they gain relative share and capital inflows during risk-off because of predictable cash flows and 50+ year dividend pedigrees. Elective-procedure exposed smaller medtechs and high-PE biotech names are the losers in a bear market where payors push for cost control; expect modest pricing pressure from payors but limited for essential devices and diagnostics. Cross-asset: flight-to-safety should compress healthcare equity betas, push funds into IG credit and high-quality names (JNJ tightening credit spreads), and reduce IV in options markets; a stronger USD would modestly pressure ABT reported growth in EM-heavy markets.

Risk assessment: Tail risks include sudden FDA recalls, large adverse trial readouts, or a reimbursement shock (e.g., Medicare policy change) that could erase 20–40% of near-term value for affected products. Immediate (days) risks: earnings/volume prints and macro-driven equity selloffs; short-term (weeks–6 months): guidance revisions and Libre adoption cadence; long-term (1–3 years): Libre penetration vs competitors and pipeline/regulatory outcomes. Hidden dependencies: hospital capital spending cycles, payor contracts, and integration risk from acquisitions (diagnostics buyouts) that can shift margins by ±200–500bp.

Trade implications: Direct: establish a 2–3% long position in ABT for 12–24 months targeting 20–35% upside if Libre market share grows 300–400 bps annually; add a 1–2% long in JNJ for income and defensive ballast. Pair: long ABT / short JNJ (equal notional) to express growth-over-income exposure for 12–18 months; expect relative outperformance if ABT grows revenue >6% YoY. Options: sell JNJ 30–90d cash-secured puts 3–5% OTM to collect yield if IV remains low; buy ABT 12–18 month LEAPS (0.5–0.6 delta) or a debit call spread to cap cost. Entry: scale on 3–8% pullbacks or on ABT volume prints showing Libre monthly growth >5% MoM.

Contrarian angles: Consensus underrates ABT’s Libre optionality — underpenetrated diabetes markets can drive sustained high-teens EPS CAGR absent reimbursement shocks; conversely, JNJ’s litigation tail (historical talc/legal volatility) and slower pharma throughput are underappreciated. The market may be underpricing the asymmetric upside of diagnostics and CGM expansion (ABT) while overpaying for defensive stability (JNJ) — mispricing ripe for pair trades. Watch for unintended outcomes: rapid Libre share gains could attract aggressive competition or regulatory scrutiny; set hard stops (10% absolute or fundamental miss triggers such as Libre revenue <–5% YoY).

Key Decisions for Investors

• Establish a 2–3% long position in ABT (Abbott) and hold 12–24 months; target 20–35% total return conditional on Libre revenue growth >300–400 bps/year and cut if Libre revenue misses consensus by >5% YoY.
• Add a 1–2% defensive long in JNJ for income and credit exposure; simultaneously sell 30–90 day cash-secured puts 3–5% OTM to enhance yield, rolling if assigned or if 10-year Treasury >4.5%.
• Implement a pair trade: long ABT / short JNJ (equal notional) sized ~1–2% net exposure for 12–18 months to capture ABT's growth premium; trim if ABT/JNJ relative performance reverses by >10% or if ABT guidance is cut.
• Use options to express asymmetric upside: buy 12–18 month ABT LEAPS (0.5–0.6 delta) or a 12-month call debit spread to limit premium; avoid long-dated volatility buys on JNJ given low IV and pay down risk by selling short-dated OTM calls if collecting yield.